Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Pomalidomide

HY-10984

(CC-4047; CC4047; CC 4047)

Pomalidomide

Pomalidomide Chemical Structure

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $84 In-stock
50 mg $200 In-stock
100 mg $240 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €54 In-stock
5 mg €49 In-stock
10 mg €82 In-stock
50 mg €196 In-stock
100 mg €235 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Pomalidomide
Cat. No.: HY-10984

Pomalidomide Data Sheet

  • View current batch:

    Purity: 99.68%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    NMR

    Pdf Version

    LCMS

Customer View

Related Compound Libraries

Biological Activity of Pomalidomide

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.
IC50 Value: 13 nM
Target: TNF-alpha
in vitro: Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM.
in vivo: Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity.


 

Chemical Information

M.Wt 273.24 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C13H11N3O4
CAS No 19171-19-8
Solvent & Solubility

DMSO ≥52mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 3.6598 mL 18.2989 mL 36.5979 mL
5 mM 0.7320 mL 3.6598 mL 7.3196 mL
10 mM 0.3660 mL 1.8299 mL 3.6598 mL

Clinical Information of Pomalidomide

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Pomalidomide Celgene Corp Myelofibrosis 31-AUG-10 31-MAR-17 Phase 3 06-NOV-13
Celgene Corp Multiple myeloma 31-MAR-11 30-JUN-13 Phase 3 07-MAY-13
Celgene Corp Multiple myeloma 31-MAR-11 31-MAY-13 Phase 3 07-NOV-13
Celgene Corp Multiple myeloma 31-DEC-12 31-JAN-17 Phase 3 23-OCT-13
Celgene Corp Multiple myeloma 30-NOV-12 30-NOV-19 Phase 3 18-OCT-13

References on Pomalidomide

Inhibitor Kit

Related TNF-alpha Products

  • Bioymifi

    Bioymifi(DR5 Activator) is the first novel and potent small-molecule activatior of the TRAIL receptor DR5 in human cancer cells.

  • Necrostatin-1

    Necrostatin-1 is a specific RIP1 inhibitor and inhibits TNF-(alpha)-induced necroptosis with EC50 of 490 nM.

  • Roquinimex

    Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.